Pharma BD Deal Intelligence

Bristol-Myers Squibb Company / Anokion SA / Kanyos Bio Inc.

2019 · Co-Development · $1.3B · Terminated

Announcement Sentiment

Strongly positive

BMS and Anokion/Kanyos established a strategic collaboration on antigen-specific tolerance therapeutics for autoimmune diseases including MS, type 1 diabetes and celiac disease. BMS made an upfront equity investment plus committed to option exercise payments and milestones up to ~$1.3B.

Key facts

Announced Oct 07, 2019
Deal value $1.3B
Deal type Co-Development
Therapeutic area Multiple sclerosis, type 1 diabetes, celiac disease
Indications Multiple sclerosis, type 1 diabetes, celiac disease
Key assets Antigen-specific tolerance therapeutics
Mechanism Antigen-specific immune tolerance

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals